Darbepoetin alfa administration in patients with non-Hodgkin lymphoma and chemotherapy-induced anemia receiving (±R) CHOP. 2013

Ruth Pettengell, and Antonio Salar Silvestre, and Matthias Schwenkglenks, and Francesca Gaia Rossi, and Ulrich Duehrsen, and Gregor Verhoef, and Pieternella Johanna Lugtenburg, and Tracey Wheeler, and Beatriz Pujol, and Corinne Haioun
Haematology, St George's University of London, London SW17 0RE, UK. rpetteng@sgul.ac.uk

IMPACT NHL was a multicenter, observational study in adults with non-Hodgkin lymphoma receiving CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) chemotherapy with or without rituximab. Erythropoietin-stimulating agent treatment was given according to routine clinical practice and physician preference. In a subanalysis, outcomes were evaluated in 207 patients who received darbepoetin alfa (DA). The most common reason (81%) for initiating DA was low/declining hemoglobin (Hb) concentration. Mean (±standard deviation) duration of DA exposure was 8.8 ± 6.9 weeks (mean number of doses, 5.1 ± 4.6). Overall, 23% of patients had chemotherapy and DA treatment synchronized more than 75% of the time. At the time of DA initiation, 67% of patients had Hb concentrations in the guideline-recommended range (9-11 g/dl). Of 89 patients with Hb concentrations <10 g/dl at DA initiation and still receiving DA 5 weeks later, 92% (Kaplan-Meier) achieved Hb concentrations 10-12 g/dl between week 5 and at the end of treatment.

UI MeSH Term Description Entries
D008228 Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease. Non-Hodgkin Lymphoma,Diffuse Mixed Small and Large Cell Lymphoma,Diffuse Mixed-Cell Lymphoma,Diffuse Small Cleaved-Cell Lymphoma,Diffuse Undifferentiated Lymphoma,Lymphatic Sarcoma,Lymphoma, Atypical Diffuse Small Lymphoid,Lymphoma, Diffuse,Lymphoma, Diffuse, Mixed Lymphocytic-Histiocytic,Lymphoma, High-Grade,Lymphoma, Intermediate-Grade,Lymphoma, Low-Grade,Lymphoma, Mixed,Lymphoma, Mixed Cell, Diffuse,Lymphoma, Mixed Lymphocytic-Histiocytic,Lymphoma, Mixed Small and Large Cell, Diffuse,Lymphoma, Mixed-Cell,Lymphoma, Mixed-Cell, Diffuse,Lymphoma, Non-Hodgkin's,Lymphoma, Non-Hodgkin, Familial,Lymphoma, Non-Hodgkins,Lymphoma, Nonhodgkin's,Lymphoma, Nonhodgkins,Lymphoma, Pleomorphic,Lymphoma, Small Cleaved Cell, Diffuse,Lymphoma, Small Cleaved-Cell, Diffuse,Lymphoma, Small Non-Cleaved-Cell,Lymphoma, Small Noncleaved-Cell,Lymphoma, Small and Large Cleaved-Cell, Diffuse,Lymphoma, Undifferentiated,Lymphoma, Undifferentiated, Diffuse,Lymphosarcoma,Mixed Small and Large Cell Lymphoma, Diffuse,Mixed-Cell Lymphoma,Mixed-Cell Lymphoma, Diffuse,Non-Hodgkin's Lymphoma,Reticulosarcoma,Reticulum Cell Sarcoma,Reticulum-Cell Sarcoma,Sarcoma, Lymphatic,Sarcoma, Reticulum-Cell,Small Cleaved-Cell Lymphoma, Diffuse,Small Non-Cleaved-Cell Lymphoma,Small Noncleaved-Cell Lymphoma,Undifferentiated Lymphoma,Diffuse Lymphoma,Diffuse Lymphomas,Diffuse Mixed Cell Lymphoma,Diffuse Mixed-Cell Lymphomas,Diffuse Small Cleaved Cell Lymphoma,Diffuse Undifferentiated Lymphomas,High-Grade Lymphoma,High-Grade Lymphomas,Intermediate-Grade Lymphoma,Intermediate-Grade Lymphomas,Low-Grade Lymphoma,Low-Grade Lymphomas,Lymphatic Sarcomas,Lymphocytic-Histiocytic Lymphoma, Mixed,Lymphocytic-Histiocytic Lymphomas, Mixed,Lymphoma, Diffuse Mixed-Cell,Lymphoma, Diffuse Undifferentiated,Lymphoma, High Grade,Lymphoma, Intermediate Grade,Lymphoma, Low Grade,Lymphoma, Mixed Cell,Lymphoma, Mixed Lymphocytic Histiocytic,Lymphoma, Non Hodgkin,Lymphoma, Non Hodgkin's,Lymphoma, Non Hodgkins,Lymphoma, Nonhodgkin,Lymphoma, Small Non Cleaved Cell,Lymphoma, Small Noncleaved Cell,Lymphosarcomas,Mixed Cell Lymphoma,Mixed Cell Lymphoma, Diffuse,Mixed Lymphocytic-Histiocytic Lymphoma,Mixed Lymphocytic-Histiocytic Lymphomas,Mixed Lymphoma,Mixed Lymphomas,Mixed-Cell Lymphomas,Non Hodgkin Lymphoma,Non Hodgkin's Lymphoma,Non-Cleaved-Cell Lymphoma, Small,Non-Hodgkins Lymphoma,Noncleaved-Cell Lymphoma, Small,Nonhodgkin's Lymphoma,Nonhodgkins Lymphoma,Pleomorphic Lymphoma,Pleomorphic Lymphomas,Reticulosarcomas,Reticulum Cell Sarcomas,Reticulum-Cell Sarcomas,Sarcoma, Reticulum Cell,Small Cleaved Cell Lymphoma, Diffuse,Small Non Cleaved Cell Lymphoma,Small Non-Cleaved-Cell Lymphomas,Small Noncleaved Cell Lymphoma,Small Noncleaved-Cell Lymphomas,Undifferentiated Lymphoma, Diffuse,Undifferentiated Lymphomas
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004921 Erythropoietin Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.
D005260 Female Females
D006397 Hematinics Agents which improve the quality of the blood, increasing the hemoglobin level and the number of erythrocytes. They are used in the treatment of anemias. Erythropoiesis Stimulating Agent,Hematinic,Hematopoietic Agents,Erythropoiesis Stimulating Agents,Agent, Erythropoiesis Stimulating,Stimulating Agent, Erythropoiesis

Related Publications

Ruth Pettengell, and Antonio Salar Silvestre, and Matthias Schwenkglenks, and Francesca Gaia Rossi, and Ulrich Duehrsen, and Gregor Verhoef, and Pieternella Johanna Lugtenburg, and Tracey Wheeler, and Beatriz Pujol, and Corinne Haioun
February 2015, Nihon rinsho. Japanese journal of clinical medicine,
Ruth Pettengell, and Antonio Salar Silvestre, and Matthias Schwenkglenks, and Francesca Gaia Rossi, and Ulrich Duehrsen, and Gregor Verhoef, and Pieternella Johanna Lugtenburg, and Tracey Wheeler, and Beatriz Pujol, and Corinne Haioun
July 2006, Supportive cancer therapy,
Ruth Pettengell, and Antonio Salar Silvestre, and Matthias Schwenkglenks, and Francesca Gaia Rossi, and Ulrich Duehrsen, and Gregor Verhoef, and Pieternella Johanna Lugtenburg, and Tracey Wheeler, and Beatriz Pujol, and Corinne Haioun
December 2003, Pharmacotherapy,
Ruth Pettengell, and Antonio Salar Silvestre, and Matthias Schwenkglenks, and Francesca Gaia Rossi, and Ulrich Duehrsen, and Gregor Verhoef, and Pieternella Johanna Lugtenburg, and Tracey Wheeler, and Beatriz Pujol, and Corinne Haioun
February 2015, Journal of chemotherapy (Florence, Italy),
Ruth Pettengell, and Antonio Salar Silvestre, and Matthias Schwenkglenks, and Francesca Gaia Rossi, and Ulrich Duehrsen, and Gregor Verhoef, and Pieternella Johanna Lugtenburg, and Tracey Wheeler, and Beatriz Pujol, and Corinne Haioun
December 2003, Cancer,
Ruth Pettengell, and Antonio Salar Silvestre, and Matthias Schwenkglenks, and Francesca Gaia Rossi, and Ulrich Duehrsen, and Gregor Verhoef, and Pieternella Johanna Lugtenburg, and Tracey Wheeler, and Beatriz Pujol, and Corinne Haioun
January 2019, The Permanente journal,
Ruth Pettengell, and Antonio Salar Silvestre, and Matthias Schwenkglenks, and Francesca Gaia Rossi, and Ulrich Duehrsen, and Gregor Verhoef, and Pieternella Johanna Lugtenburg, and Tracey Wheeler, and Beatriz Pujol, and Corinne Haioun
April 2013, Current medical research and opinion,
Ruth Pettengell, and Antonio Salar Silvestre, and Matthias Schwenkglenks, and Francesca Gaia Rossi, and Ulrich Duehrsen, and Gregor Verhoef, and Pieternella Johanna Lugtenburg, and Tracey Wheeler, and Beatriz Pujol, and Corinne Haioun
October 2002, Oncology (Williston Park, N.Y.),
Ruth Pettengell, and Antonio Salar Silvestre, and Matthias Schwenkglenks, and Francesca Gaia Rossi, and Ulrich Duehrsen, and Gregor Verhoef, and Pieternella Johanna Lugtenburg, and Tracey Wheeler, and Beatriz Pujol, and Corinne Haioun
January 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
Ruth Pettengell, and Antonio Salar Silvestre, and Matthias Schwenkglenks, and Francesca Gaia Rossi, and Ulrich Duehrsen, and Gregor Verhoef, and Pieternella Johanna Lugtenburg, and Tracey Wheeler, and Beatriz Pujol, and Corinne Haioun
January 2006, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy,
Copied contents to your clipboard!